These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35630004)

  • 41. Role of EGFL7 in human cancers: A review.
    de Oliveira C; Gonçalves PG; Bidinotto LT
    J Cell Physiol; 2023 Aug; 238(8):1756-1767. PubMed ID: 37490307
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immune cells in the normal ovary and spontaneous ovarian tumors in the laying hen (Gallus domesticus) model of human ovarian cancer.
    Bradaric MJ; Penumatsa K; Barua A; Edassery SL; Yu Y; Abramowicz JS; Bahr JM; Luborsky JL
    PLoS One; 2013; 8(9):e74147. PubMed ID: 24040191
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Study of T lymphocytes infiltrating peritoneal metastases in advanced ovarian cancer: associations with vascular endothelial growth factor levels and prognosis in patients receiving platinum-based chemotherapy.
    Tsiatas ML; Gyftaki R; Liacos C; Politi E; Rodolakis A; Dimopoulos MA; Bamias A
    Int J Gynecol Cancer; 2009 Nov; 19(8):1329-34. PubMed ID: 20009885
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Epidermal growth factor-like domain 7 is a novel inhibitor of neutrophil adhesion to coronary artery endothelial cells injured by calcineurin inhibition.
    Badiwala MV; Guha D; Tumiati L; Joseph J; Ghashghai A; Ross HJ; Delgado DH; Rao V
    Circulation; 2011 Sep; 124(11 Suppl):S197-203. PubMed ID: 21911813
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Endostatin gene therapy stimulates upregulation of ICAM-1 and VCAM-1 in a metastatic renal cell carcinoma model.
    Chaves KC; Peron JP; Chammas R; Turaça LT; Pesquero JB; Braga MS; Foguer K; Schor N; Bellini MH
    Cancer Gene Ther; 2012 Aug; 19(8):558-65. PubMed ID: 22699868
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Evaluation of the intracellular expression of interleukin 17 in patients with ovarian cancer].
    Rogala E; Nowicka A; Bednarek W; Barczyński B; Wertel I; Zakrzewski M; Kotarski J
    Ginekol Pol; 2012 Jun; 83(6):424-8. PubMed ID: 22880461
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ICAM-1 expression on the surface of T lymphocytes in patients with uveitis: a comparative study between the eye and peripheral blood.
    Martin CM; Santos Lacomba M; Serrano Molina CI; Ramirez Chamond R; Collantes Estevez E
    Ophthalmologica; 2002; 216(3):203-8. PubMed ID: 12065858
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Low EGFL7 expression is associated with high lymph node spread and invasion of lymphatic vessels in colorectal cancer.
    de Oliveira C; Martins SFF; Gonçalves PG; Limone GA; Longatto-Filho A; Reis RM; Bidinotto LT
    Sci Rep; 2023 Nov; 13(1):19783. PubMed ID: 37957249
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tissue-based immune monitoring II: multiple tumor sites reveal immunologic homogeneity in serous ovarian carcinoma.
    Hagemann AR; Hagemann IS; Cadungog M; Hwang WT; Patel P; Lal P; Hammond R; Gimotty PA; Chu CS; Rubin SC; Birrer MJ; Powell DJ; Feldman MD; Coukos G
    Cancer Biol Ther; 2011 Aug; 12(4):367-77. PubMed ID: 21785280
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Increased expression of epidermal growth factor-like domain-containing protein 7 is predictive of poor prognosis in patients with hepatocellular carcinoma.
    Yang C; Wang YL; Sun D; Zhu XL; Li Z; Ni CF
    J Cancer Res Ther; 2018; 14(4):867-872. PubMed ID: 29970668
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma.
    Kim KH; Choi KU; Kim A; Lee SJ; Lee JH; Suh DS; Kwon BS; Hwang C
    J Ovarian Res; 2019 Jun; 12(1):56. PubMed ID: 31208449
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
    Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
    Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
    Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
    Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Lymphocyte activation markers in patients with ovarian cancer].
    Nowicka A; Rogala E; Bednarek W; Barczyński B; Wertel I; Piekarczyk W; Kotarski J
    Ginekol Pol; 2012 Oct; 83(10):737-43. PubMed ID: 23383558
    [TBL] [Abstract][Full Text] [Related]  

  • 55. T cell infiltration and MHC I and II expression in the presence of tumor antigens: An immunohistochemical study in patients with serous epithelial ovarian cancer.
    Nijman HW; van Diest PJ; Poort-Keesom RJ; von Mensdorff-Pouilly S; Verstraeten RA; Kummer A; Meijer CJ; Melief CJ; Hilgers J; Kenemans P
    Eur J Obstet Gynecol Reprod Biol; 2001 Jan; 94(1):114-20. PubMed ID: 11134836
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cancer Stem Cell-Related Marker NANOG Expression in Ovarian Serous Tumors: A Clinicopathological Study of 159 Cases.
    Kenda Šuster N; Frković Grazio S; Virant-Klun I; Verdenik I; Smrkolj Š
    Int J Gynecol Cancer; 2017 Nov; 27(9):2006-2013. PubMed ID: 28906309
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunological peculiarities of CD-56-positive serous ovarian adenocarcinoma.
    Zueva EV; Kairbayeva MZ; Nikogosyan SO; Mozhenkova AV; Digaeva MA; Tereshkina IV; Tupitsyn NN
    Bull Exp Biol Med; 2010 Oct; 149(5):604-8. PubMed ID: 21165398
    [TBL] [Abstract][Full Text] [Related]  

  • 58. VE-statin/Egfl7 expression in malignant glioma and its relevant molecular network.
    Huang C; Yuan X; Wan Y; Liu F; Chen X; Zhan X; Li X
    Int J Clin Exp Pathol; 2014; 7(3):1022-31. PubMed ID: 24696719
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
    Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
    Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
    Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
    Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.